knowledge -WSS

knowledge

author：leisure time 2025-10-01 15:31:40 - browse：75

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： GSK Flovent asthma inhalers replaced by authorized generics

WSS

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Researchers on aging grapple with how to calculate biological age

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

UCB departs biotech trade group BIO

Making AI in medicine accessible to smaller, and rural hospitals

focus

knowledge

explore

Novavax promises a turnaround & Lilly roils the obesity market

Medicare says breakthrough device reimbursement rule to come by summer

Jerome Adams on the need for new antivirals for Covid

Study: AI not yet building 'n

BioMarin wins approval for gene therapy to treat hemophilia A

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Virginia high school admissions case could be legal follow

H5N1 communication has been strictly for the birds

In Memoriam: Notable people who died in 2023

Ahead of JPM, here's who's profiting most in health care

hotspot

Ahead of JPM, here's who's profiting most in health care

Readout LOUD podcast: What to know about H5N1 bird flu

J&J to buy cancer drug developer Ambrx Biopharma

AdventHealth escalates lawsuit against insurance vendor Multiplan

Brain worms: The science behind RFK Jr.'s parasitic infection

Burning questions for the 2024 JPM Healthcare Conference

explore

hotspot

focus

focus